...
机译:Orlotinib的随机阶段III试验与Docetaxel作为高级非小细胞肺癌患者的二线或第三线疗法:多西紫杉醇和厄洛替尼肺癌试验(Delta)
Department of Internal Medicine National Hospital Organization Kinki-Chuo Chest Medical Center;
Center for Advanced Medicine and Clinical Research Nagoya University Hospital Japan;
Department of Internal Medicine National Hospital Organization Kinki-Chuo Chest Medical Center;
National Hospital Organization Kochi Hospital Kochi India;
National Hospital Organization Nagasaki Medical Center Nagasaki Japan;
National Hospital Organization Hirosaki Hospital Hirosaki Japan;
National Hospital Organization Mie Chuo Medical Center Tsu Japan;
National Hospital Organization Shikoku Cancer Center Matsuyama Japan;
National Hospital Organization Mito Medical Center Mito Japan;
National Hospital Organization Tokyo Hospital Japan;
National Hospital Organization Disaster Medical Center Tokyo Japan;
National Hospital Organization Yokohama Medical Center Yokohama Japan;
National Hospital Organization Fukuoka East Medical Center Fukuoka Japan;
National Hospital Organization Ureshino Medical Center Ureshino Japan;
National Hospital Organization Nishigunma Hospital Gunma Japan;
Department of Internal Medicine National Hospital Organization Kinki-Chuo Chest Medical Center;
Koyo Hospital Osaka Japan;
National Hospital Organization Nagoya Medical Center Nagoya Japan;
Aichi Medical University School of Medicine Aichi Japan;
机译:Orlotinib的随机阶段III试验与Docetaxel作为高级非小细胞肺癌患者的二线或第三线疗法:多西紫杉醇和厄洛替尼肺癌试验(Delta)
机译:一线化疗失败后非小细胞肺癌患者中序贯厄洛替尼联合多西他赛与多西他赛的随机开放非对照多中心II期试验:GFPC 10.02研究(第85卷,第415页,2014年)
机译:一线化疗失败后的非小细胞肺癌患者的序贯厄洛替尼联合多西他赛与单独多西他赛的随机开放式非比较性多中心II期临床研究:GFPC 10.02研究。
机译:培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
机译:Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
机译:厄洛替尼卡博替尼或厄洛替尼加卡博替尼作为EGFR野生型晚期非小细胞肺癌患者的二线或三线治疗(ECOG-ACRIN 1512):一项2期随机对照试验
机译:随机的Erlotinib对多西紫杉醇的Arlotinib与多西紫杉醇的试验失败的一线铂类双细胞化疗,由Veristrat良好的veristrat差分层。欧洲胸肿瘤学平台(ETOP)重点肺试验